NorDiag ASA Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2012
May 24, 2012 at 02:02 am EDT
Share
NorDiag ASA reported unaudited consolidated earnings results for the first quarter ended March 31, 2012. For the quarter, the company reported total operating revenues of NOK 7,555,000 compared to NOK 7,688,000 a year ago. LBITDA before restructuring was NOK 5,075,000 compared to NOK 9,919,000 a year ago. LBITDA after restructuring was NOK 6,347,000 compared to NOK 9,919,000 a year ago. LBIT was NOK 7,183,000 compared to NOK 11,734,000 a year ago. Loss before taxes was NOK 7,595,000 compared to NOK 12,700,000 a year ago. Loss from continuing operations was NOK 7,595,000 compared to NOK 12,700,000 a year ago. Net loss attributable to the owners of the company was NOK 7,595,000 or NOK 0.03 per diluted share compared to NOK 11,968,000 or NOK 0.17 per diluted share a year ago. Net cash from operating activities was NOK 6,152,000 compared to NOK 12,823,000 a year ago. Investment in intangible assets was NOK 391,000 compared to NOK 721,000 a year ago. Investment in non-current assets was NOK 21,000 compared to NOK 690,000 a year ago.
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Companyâs products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
NORDA ASA 
